223 related articles for article (PubMed ID: 9105540)
21. N4-unsubstituted N1-arylpiperazines as high-affinity 5-HT1A receptor ligands.
Kuipers W; van Wijngaarden I; Kruse CG; ter Horst-van Amstel M; Tulp MT; IJzerman AP
J Med Chem; 1995 May; 38(11):1942-54. PubMed ID: 7783126
[TBL] [Abstract][Full Text] [Related]
22. Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.
Millan MJ; Canton H; Gobert A; Lejeune F; Rivet JM; Bervoets K; Brocco M; Widdowson P; Mennini T; Audinot V
J Pharmacol Exp Ther; 1994 Jan; 268(1):337-52. PubMed ID: 8301575
[TBL] [Abstract][Full Text] [Related]
23. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
Schreiber R; Brocco M; Audinot V; Gobert A; Veiga S; Millan MJ
J Pharmacol Exp Ther; 1995 Apr; 273(1):101-12. PubMed ID: 7714755
[TBL] [Abstract][Full Text] [Related]
24. Influence of the aliphatic spacer length on the 5-HT1A receptor activity of new arylpiperazines with an indazole system.
Paluchowska MH; Duszyńska B; Kłodzińska A; Tatarczyńska E
Pol J Pharmacol; 2000; 52(3):209-16. PubMed ID: 11055578
[TBL] [Abstract][Full Text] [Related]
25. New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities.
Feenstra RW; de Moes J; Hofma JJ; Kling H; Kuipers W; Long SK; Tulp MT; van der Heyden JA; Kruse CG
Bioorg Med Chem Lett; 2001 Sep; 11(17):2345-9. PubMed ID: 11527728
[TBL] [Abstract][Full Text] [Related]
26. Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists.
Millan MJ; Rivet JM; Canton H; Le Marouille-Girardon S; Gobert A
J Pharmacol Exp Ther; 1993 Mar; 264(3):1364-76. PubMed ID: 8450471
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and properties of several heterocyclic dopaminergic ligands.
Kostić S; Soskić V; Joksimović J
Arzneimittelforschung; 1994 Jun; 44(6):697-702. PubMed ID: 7914413
[TBL] [Abstract][Full Text] [Related]
28. New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
Liégeois JF; Eyrolles L; Ellenbroek BA; Lejeune C; Carato P; Bruhwyler J; Géczy J; Damas J; Delarge J
J Med Chem; 2002 Nov; 45(23):5136-49. PubMed ID: 12408724
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D(2), serotonin, and GABA(A) receptors.
Asproni B; Pau A; Bitti M; Melosu M; Cerri R; Dazzi L; Seu E; Maciocco E; Sanna E; Busonero F; Talani G; Pusceddu L; Altomare C; Trapani G; Biggio G
J Med Chem; 2002 Oct; 45(21):4655-68. PubMed ID: 12361392
[TBL] [Abstract][Full Text] [Related]
30. Novel 4-alkyl-1-arylpiperazines and 1,2,3,4-tetrahydroisoquinolines containing diphenylmethylamino or diphenylmethoxy fragment with differentiated 5-HT1A/5-HT2A/D2 receptor activity.
Paluchowska MH; Mokrosz MJ; Charakchieva-Minol S; Duszyńska B; Kozioł A; Wesołowska A; Stachowicz K; Chojnacka-Wójcik E
Pol J Pharmacol; 2003; 55(4):543-52. PubMed ID: 14581712
[TBL] [Abstract][Full Text] [Related]
31. Characterization of potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazines.
Peglion JL; Canton H; Bervoets K; Audinot V; Brocco M; Gobert A; Le Marouille-Girardon S; Millan MJ
J Med Chem; 1995 Sep; 38(20):4044-55. PubMed ID: 7562940
[TBL] [Abstract][Full Text] [Related]
32. Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse.
Laporte AM; Lima L; Gozlan H; Hamon M
Eur J Pharmacol; 1994 Dec; 271(2-3):505-14. PubMed ID: 7705451
[TBL] [Abstract][Full Text] [Related]
33. [[(Arylpiperazinyl)alkyl]thio]thieno[2,3-d]pyrimidinone derivatives as high-affinity, selective 5-HT1A receptor ligands.
Modica M; Santagati M; Russo F; Parotti L; De Gioia L; Selvaggini C; Salmona M; Mennini T
J Med Chem; 1997 Feb; 40(4):574-85. PubMed ID: 9046348
[TBL] [Abstract][Full Text] [Related]
34. The effect of chronic treatment with a novel aryl-piperazine antipsychotic on monoamine receptors in rat brain.
Shapiro LA; Offord SJ; Ordway GA
Brain Res; 1995 Apr; 677(2):250-6. PubMed ID: 7552250
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and dopaminergic features of six novel 3-arylpiperidines.
Kostic-Rajacic A; Soskic V; Joksimovic J
Boll Chim Farm; 1998 Nov; 137(10):417-21. PubMed ID: 10025971
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of novel 5-substituted 3-amino-3,4-dihydro-2H-1-benzopyran derivatives and their interactions with the 5-HT1A receptor.
Hammarberg E; Nordvall G; Leideborg R; Nylöf M; Hanson S; Johansson L; Thorberg SO; Tolf BR; Jerning E; Svantesson GT; Mohell N; Ahlgren C; Westlind-Danielsson A; Csöregh I; Johansson R
J Med Chem; 2000 Jul; 43(15):2837-50. PubMed ID: 10956192
[TBL] [Abstract][Full Text] [Related]
37. Atypical in vitro and in vivo binding of [3H]S-14506 to brain 5-HT1A receptors.
Lima L; Laporte AM; Gaymard C; Spedding M; Mocaër E; Hamon M
J Neural Transm (Vienna); 1997; 104(10):1059-75. PubMed ID: 9503258
[TBL] [Abstract][Full Text] [Related]
38. S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors.
Millan MJ; Rivet JM; Canton H; Lejeune F; Bervoets K; Brocco M; Gobert A; Lefebvre de Ladonchamps B; Le Marouille-Girardon S; Verriele L
J Pharmacol Exp Ther; 1992 Aug; 262(2):451-63. PubMed ID: 1323650
[TBL] [Abstract][Full Text] [Related]
39. C5-substituted derivatives of 5-OMe-BPAT: synthesis and interactions with dopamine D2 and serotonin 5-HT1A receptors.
Homan EJ; Tulp MT; Nilsson JE; Wikström HV; Grol CJ
Bioorg Med Chem; 1999 Nov; 7(11):2541-8. PubMed ID: 10632064
[TBL] [Abstract][Full Text] [Related]
40. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
Gogos A; Kwek P; Chavez C; van den Buuse M
J Pharmacol Exp Ther; 2010 Apr; 333(1):218-27. PubMed ID: 20042529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
